Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 33, 2015, Pages 10473-10478

  Corti, Davide ^a,b   Zhao, Jincun ^c,d   Pedotti, Mattia ^a   Simonelli, Luca ^a   Agnihothram, Sudhakar ^e   Fett, Craig ^e   Fernandez Rodriguez, Blanca ^a   Foglierini, Mathilde ^a   Agatic, Gloria ^b   Vanzetta, Fabrizia ^b   Gopal, Robin ^f   Langrish, Christopher J ^g   Barrett, Nicholas A ^g,h   Sallusto, Federica ^a   Baric, Ralph S ^e,i   Varani, Luca ^a   Zambon, Maria ^f   Perlman, Stanley ^c   Lanzavecchia, Antonio ^a,j  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^b Humabs BioMed SA ^*  (Switzerland)

^c UNIVERSITY OF IOWA   (United States)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ IL   (United States)

^j ETH ZURICH   (Switzerland)

more..

Author keywords

Emerging viruses; MERS CoV; Neutralizing antibody; Serotherapy

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; HUMAN MONOCLONAL ANTIBODY; LCA 60; UNCLASSIFIED DRUG; CORONAVIRUS SPIKE GLYCOPROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN BINDING; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG EFFICACY; MEMORY CELL; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; B LYMPHOCYTE; BAGG ALBINO MOUSE; CHEMISTRY; CHO CELL LINE; CONFORMATION; CORONAVIRUS INFECTION; CRICETULUS; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMSTER; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MALE; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; SEQUENCE HOMOLOGY; VIROLOGY;

ADENOVIRIDAE; CAMELIDAE; CORONAVIRUS; CRICETULUS GRISEUS; MUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; BINDING SITES; CHO CELLS; CORONAVIRUS INFECTIONS; CRICETINAE; CRICETULUS; DIPEPTIDYL PEPTIDASE 4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; SEQUENCE HOMOLOGY, AMINO ACID; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRAL VACCINES;

EID: 84939863145     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510199112     Document Type: Article

References (32)

1. Assiri A, et al.; KSA MERS-CoV Investigation Team (2013) Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369(5):407-416.
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814-1820.
3. Ge X-Y, et al. (2013) Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503(7477):535-538.
4. Memish ZA, et al. (2013) Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 19(11):1819-1823.
5. Haagmans BL, et al. (2014) Middle East respiratory syndrome coronavirus in dromedary camels: An outbreak investigation. Lancet Infect Dis 14(2):140-145.
6. Kupferschmidt K (2015) Infectious diseases. MERS surges again, but pandemic jitters ease. Science 347(6228):1296-1297.
7. Hofmann H, et al. (2004) S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 78(12):6134-6142.
8. Gierer S, et al. (2013) The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 87(10):5502-5511.
9. Raj VS, et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440):251-254.
10. Lu G, et al. (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500(7461):227-231.
11. Wang N, et al. (2013) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23(8):986-993.
12. Tang X-C, et al. (2014) Identification of human neutralizing antibodies against MERS- CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 111(19): E2018-E2026.
13. Ying T, et al. (2014) Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 88(14):7796-7805.
14. Bermingham A, et al. (2012) Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 17(40):20290.
15. Pedotti M, Simonelli L, Livoti E, Varani L (2011) Computational docking of antibody-antigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin. Int J Mol Sci 12(1):226-251.
16. Gray JJ, et al. (2003) Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J Mol Biol 331(1):281-299.
17. Zhao J, et al. (2014) Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 111(13):4970-4975.
18. Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 145(8):599-609.
19. Cheng Y, et al. (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24(1):44-46.
20. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357(14):1450-1451.
21. Hung IF, et al. (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52(4): 447-456.
22. Respaud R, Vecellio L, Diot P, Heuze Vourc'h N (2014) Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv 12(6):1027-1039.
23. Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P (2015) Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza monoclonal antibodies. Antimicrob Agents Chemother 59(7):4162-4172.
24. Maillet A, et al. (2011) The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm Res 28(9):2147-2156.
25. Traggiai E, et al. (2004) An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 10(8): 871-875.
26. Tiller T, et al. (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329(1-2):112-124.
27. Temperton NJ, et al. (2005) Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis 11(3):411-416.
28. Temperton NJ, et al. (2007) A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respi Viruses 1(3):105-112.
29. Marcatili P, Rosi A, Tramontano A (2008) PIGS: Automatic prediction of antibody structures. Bioinformatics 24(17):1953-1954.
30. Sircar A, Kim ET, Gray JJ (2009) RosettaAntibody: Antibody variable region homology modeling server. Nucleic Acids Res 37(Web Server issue):W474-W479.
31. Simonelli L, et al. (2010) Rapid structural characterization of human antibody-antigen complexes through experimentally validated computational docking. J Mol Biol 396(5):1491-1507.
32. Agnihothram S, et al. (2014) Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis 209(7):995-1006.